Elena Parovichnikova
National Research Center for Hematology · National Research Medical Center for Hematology · Nathional Medical Research Center for Hematology Moscow Russia 125167
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Elena Parovichnikova as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:21 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07883135 · Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell LymphomasNational Research Center for Hematology, Russia · recruiting · Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Relapsed or Refractory B-cell Lymphoma · principal investigator
- N/ANCT06237192 · MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult PatientsNational Research Center for Hematology, Russia · recruiting · Precursor Cell Lymphoblastic Leukemia-Lymphoma · study director
- Ph3NCT06188676 · Nivolumab 40 mg in Combination With Chemo-Immunotherapy for Newly Diagnosed Primary Mediastinal B-Cell LymphomaNational Research Center for Hematology, Russia · active not recruiting · Primary Mediastinal Lymphoma · study director
- Ph2NCT05660993 · Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin LymphomaNational Research Center for Hematology, Russia · unknown · Hodgkin Lymphoma · study director
- Ph3NCT05158608 · Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD ProphylaxisNational Research Center for Hematology, Russia · unknown · Graft Versus Host Disease, Hematologic Malignancy, Cyclophosphamide Adverse Reaction · principal investigator
- N/ANCT04422470 · Registry of Patients With Hematologic Disease and COVID-19 in RussiaNational Research Center for Hematology, Russia · completed · Coronavirus Infection and Hematologic Diseases · study chair
- Ph2NCT01941394 · Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis TransplantationNational Research Center for Hematology, Russia · unknown · Graft-versus-host Disease, Relapse · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:21 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:21 UTC. The ranking covers the 200 most relevant of 31 PubMed records, and a shared surname and initials can bring in a namesake. All 31 on PubMed
- Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia.Hematology · 201959 citationsRCR 2.3
- Analysis of results of acute graft-versus-host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation.Biochemistry (Mosc) · 201426 citationsRCR 0.9
- T Cell and Cytokine Dynamics in the Blood of Patients after Hematopoietic Stem Cell Transplantation and Multipotent Mesenchymal Stromal Cell Administration.Transplant Cell Ther · 20239 citationsRCR 1.0
- 7 citationsRCR 0.2
- 6 citationsRCR 0.4
- [Results of the treatment of adult acute lymphoblastic leukemia according to ALL-2005 protocol as a basis for new trials].Ter Arkh · 20095 citationsRCR 0.1
- 4 citationsRCR 0.1
- 3 citationsRCR 0.1
- 2 citationsRCR 0.1
- [Adult B-cell acute lymphoblastic leukemias: Conclusions of the Russian prospective multicenter study ALL-2009].Ter Arkh · 20172 citationsRCR 0.1